RET and ovarian neoplasm: Local sequencing analysis of a biopsy from the primary ovarian tumor collected 2.5 months prior to the study start, approximately 3 weeks before cessation of letrozole therapy, revealed the presence of RET and TrkA (NTRK1) protocol-defined mutations.